Neuropace financials
$13.94−1.48%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.8M | $22.1M | $26.6M | $27.4M | $19.5M | $22.5M | $21.5M | $21.1M | $19.3M | $18.1M | $18.0M | $16.4M |
| Gross profit | $18.9M | $18.0M | $20.6M | $21.2M | $16.2M | $17.3M | $16.2M | $15.4M | $14.1M | $13.3M | $13.5M | $12.2M |
| Gross margin | 82.8% | 81.8% | 77.4% | 77.4% | 83.1% | 77.0% | 75.4% | 73.2% | 73.4% | 73.6% | 75.2% | 74.5% |
| Operating income | -$5.1M | -$5.6M | -$1.8M | -$2.6M | -$8.2M | -$5.1M | -$3.7M | -$4.2M | -$6.2M | -$7.5M | -$5.1M | -$6.0M |
| Net income | -$6.2M | -$6.7M | -$2.7M | -$3.5M | -$8.7M | -$6.6M | -$5.3M | -$5.5M | -$7.5M | -$8.9M | -$6.2M | -$7.3M |
| Net margin | −27.2% | −30.3% | −10.3% | −12.8% | −44.4% | −29.3% | −24.5% | −25.9% | −39.0% | −49.2% | −34.4% | −44.2% |
| Diluted EPS | $-0.18 | $-0.20 | $-0.08 | $-0.11 | $-0.26 | $-0.21 | $-0.18 | $-0.19 | $-0.26 | $-0.32 | $-0.23 | $-0.28 |
| EBITDA | -$5.1M | -$5.5M | -$1.7M | -$2.5M | -$8.1M | -$5.1M | -$3.6M | -$4.2M | -$6.2M | -$7.5M | -$5.0M | -$5.9M |
| Operating cash flow | -$3.9M | -$5.9M | $506.0K | -$1.9M | -$2.1M | -$7.5M | -$4.8M | -$1.7M | -$3.9M | -$7.5M | -$3.3M | -$2.3M |
| Free cash flow | -$4.0M | -$6.0M | $409.0K | -$2.0M | -$2.3M | -$7.5M | -$4.8M | -$1.8M | -$4.0M | -$7.6M | -$3.4M | -$2.3M |
| Diluted shares | 34.1M | 33.7M | 33.4M | 33.1M | 32.9M | 31.5M | 29.9M | 29.4M | 28.9M | 28.3M | 26.8M | 26.0M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $12.5M | $14.8M | $21.7M | $20.6M | $22.9M | $27.0M |
| Short-term investments | $39.2M | $39.2M | $39.4M | $39.4M | $39.3M | $39.2M |
| Total debt | $59.0M | $59.0M | $58.9M | $58.7M | $58.6M | $59.8M |
| Total assets | $97.0M | $98.9M | $105.6M | $107.3M | $106.1M | $110.2M |
| Total liabilities | $85.1M | $84.4M | $86.5M | $88.7M | $86.7M | $85.9M |
| Shareholders' equity | $11.9M | $14.5M | $19.0M | $18.5M | $19.4M | $24.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology